Oculis Holding Ag (OCS)
NASDAQ:OCS
Want to see OCS full AI Analyst Report?
Top Page
Oculis Holding
(NASDAQ:OCS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$22.50
▼(-18.06% Downside)
Action:Reiterated
Date:05/30/26
OCS scores low primarily due to heavy ongoing losses and persistent free-cash-flow burn despite minimal revenue, which raises dilution/funding risk. The technical picture also weakens the score as price trades below key moving averages with negative MACD. The main offsetting strength is a low-debt, well-capitalized balance sheet that provides financial flexibility.
Positive Factors
Balance sheet strength
Very low leverage and a sizable equity base provide durable financial flexibility. This structural strength lowers bankruptcy and refinancing risk, supports continued R&D spending across multi-year clinical programs, and gives management time to de-risk assets before needing large external financing.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow at roughly -$60M TTM is a structural drain on capital. Over months this burn necessitates either material cost cuts or ongoing financing, which can dilute shareholders or constrain program investment if funding conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a sizable equity base provide durable financial flexibility. This structural strength lowers bankruptcy and refinancing risk, supports continued R&D spending across multi-year clinical programs, and gives management time to de-risk assets before needing large external financing.
Read all positive factors
Oculis Holding (OCS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.70B
Dividend YieldN/A
Average Volume (3M)472.52K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue GrowthN/A
EPS Growth19.41%
CountryUS
Employees49
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.73
Shares Outstanding57,169,476
10 Day Avg. Volume394,098
30 Day Avg. Volume472,520
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue2.51K
Enterprise Value/Gross Profit-86.96
Enterprise Value/Ebitda-14.94
Forecast
1Y Price Target
$52.75Price Target Upside92.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$5.27M
Oculis Holding Business Overview & Revenue Model
Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in ...
How the Company Makes Money
null...
Oculis Holding Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 504.00K | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.56M | 0.00 | -51.40M | 0.00 | 0.00 | 0.00 |
| EBITDA | -84.74M | -79.15M | -72.80M | -87.09M | -31.90M | -13.17M |
| Net Income | -95.06M | -94.51M | -85.78M | -88.80M | -38.70M | -18.55M |
Balance Sheet | ||||||
| Total Assets | 243.26M | 236.23M | 120.35M | 114.35M | 37.06M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 221.37M | 213.25M | 98.66M | 91.65M | 19.79M | 46.28M |
| Total Debt | 2.24M | 2.32M | 1.18M | 605.00K | 123.08M | 114.27M |
| Total Liabilities | 47.20M | 39.94M | 46.97M | 20.63M | 135.05M | 119.00M |
| Stockholders Equity | 196.06M | 196.29M | 73.38M | 93.73M | -97.99M | -60.95M |
Cash Flow | ||||||
| Free Cash Flow | -62.47M | -62.51M | -47.73M | -53.89M | -28.62M | -13.85M |
| Operating Cash Flow | -62.18M | -62.22M | -47.50M | -53.84M | -25.07M | -13.82M |
| Investing Cash Flow | -35.56M | -59.38M | -17.56M | -54.21M | -3.55M | -28.00K |
| Financing Cash Flow | 105.86M | 178.60M | 54.03M | 129.67M | 1.71M | 55.19M |
Oculis Holding Technical Analysis
Negative
27.46
Price Trends
27.67
Negative
27.33
Negative
23.22
Negative
Market Momentum
-0.11
Positive
32.17
Neutral
46.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Negative. The current price of 27.46 is below the 20-day moving average (MA) of 29.40, below the 50-day MA of 27.67, and above the 200-day MA of 23.22, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 32.17 is Neutral, neither overbought nor oversold. The STOCH value of 46.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OCS.
Oculis Holding Risk Analysis
Oculis Holding disclosed 95 risk factors in its most recent earnings report. Oculis Holding reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oculis Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $9.83B | -30.96 | -43.02% | ― | -100.00% | -24.90% | |
60 Neutral | $6.26B | -141.75 | -31.25% | ― | ― | 22.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $452.77M | -2.90 | -43.82% | ― | ― | ― | |
47 Neutral | $1.13B | -4.30 | -110.54% | ― | -86.41% | -45.44% | |
47 Neutral | $933.45M | -4.55 | -153.61% | ― | 1.92% | -1130.30% | |
46 Neutral | $1.70B | -10.98 | -57.09% | ― | ― | 19.41% |
* Healthcare Sector Average
OCS
Oculis Holding
22.71
3.25
16.74%
EYPT
EyePoint Pharmaceuticals
13.58
6.34
87.57%
SYRE
Spyre Therapeutics
73.50
58.22
381.02%
PRAX
Praxis Precision Medicines
349.97
311.42
807.83%
SPRY
ARS Pharmaceuticals
9.07
-5.36
-37.14%
UPB
Upstream Bio, Inc.
8.36
-0.87
-9.43%
Oculis Holding Corporate Events
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
May 14, 2026
On May 13, 2026, Oculis Holding AG held its 2026 Annual General Meeting in Zug, Switzerland, where shareholders approved all agenda items, including the 2025 annual and consolidated financial statements, despite a standalone statutory loss of CHF ...
Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results
May 11, 2026
On May 11, 2026, Oculis Holding AG reported unaudited financial results for the three months ended March 31, 2026, filing a Form 6-K with the U.S. Securities and Exchange Commission that included interim financial statements and management’s...
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
Apr 21, 2026
Oculis Holding AG announced on April 21, 2026 that it has published the invitation to its 2026 Annual General Meeting, to be held in Zug, Switzerland, on May 13, 2026, with the meeting available in person and via broadcast but without a virtual pa...
Oculis Files 2025 Financials and Renews $100 Million ATM Program
Mar 4, 2026
On March 4, 2026, Oculis Holding AG filed its 2025 IFRS consolidated and statutory financial statements, which received an unqualified audit opinion confirming a true and fair view under IFRS and Swiss law. The audit highlighted research and devel...
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
Mar 3, 2026
On March 3, 2026, Oculis reported its fourth-quarter and full-year 2025 results, highlighting a transformative year marked by clinical advances and a strengthened balance sheet. Cash, cash equivalents and short-term investments rose to $268.7 mill...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.